ERYTECH Pharma S.A. (ERYP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ERYTECH Pharma S.A. (ERYP) with AI Score 51/100 (Hold). ERYTECH Pharma S. A. is a clinical-stage biopharmaceutical company focused on developing red blood cell-based therapeutics for cancer and orphan diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026ERYTECH Pharma S.A. (ERYP) Healthcare & Pipeline Overview
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company specializing in red blood cell-based therapeutics for oncology and orphan diseases, with a focus on its lead product candidate, eryaspase, currently in Phase 3 clinical development for second-line pancreatic cancer, positioning it within the competitive biotechnology landscape.
Investment Thesis
ERYTECH Pharma S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful completion of the Phase 3 clinical trial for eryaspase in second-line pancreatic cancer, with potential FDA approval and subsequent commercialization. Positive results could significantly increase the company's market capitalization, currently at $0.05 billion. The company's negative profit margin of -1771.3% highlights its reliance on clinical trial outcomes and future revenue generation. Key catalysts include the progression of eryaspase through clinical trials and potential partnerships for commercialization. However, the investment is subject to significant risks, including clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The high beta of 2.13 indicates significant volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- Eryaspase is in Phase 3 clinical development for second-line pancreatic cancer, representing a significant potential market opportunity.
- The company has a gross margin of 100.0%, reflecting the nature of its biopharmaceutical business model.
- ERYTECH's market capitalization is $0.05 billion, indicating its small-cap status within the biotechnology industry.
- The company's profit margin is -1771.3%, highlighting its current lack of profitability due to ongoing research and development expenses.
- ERYTECH's beta is 2.13, indicating higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary red blood cell encapsulation technology.
- Lead product candidate in Phase 3 clinical development.
- Potential for orphan drug designation.
- Experienced management team.
Weaknesses
- Limited financial resources.
- High dependence on the success of eryaspase.
- Lack of commercial infrastructure.
- Negative profit margin.
Catalysts
- Upcoming: Data readout from the Phase 3 clinical trial of eryaspase in second-line pancreatic cancer expected in Q4 2026.
- Upcoming: Initiation of a Phase 2 clinical trial of eryaspase in a new cancer indication planned for Q2 2027.
- Ongoing: Continued enrollment of patients in the Phase 2 clinical trial of eryaspase in triple-negative breast cancer.
- Ongoing: Potential for securing partnerships with larger pharmaceutical companies for the development and commercialization of eryaspase.
Risks
- Potential: Failure of the Phase 3 clinical trial of eryaspase in second-line pancreatic cancer.
- Potential: Regulatory delays or rejection of eryaspase by health authorities.
- Ongoing: Competition from established pharmaceutical companies with greater resources and broader pipelines.
- Ongoing: Dependence on the success of eryaspase, with limited diversification of the product pipeline.
- Potential: Difficulty in securing funding to support ongoing research and development activities.
Growth Opportunities
- Expansion into New Therapeutic Areas: ERYTECH has the opportunity to leverage its red blood cell encapsulation technology to develop therapies for other types of cancer and orphan diseases. The market for orphan drugs is particularly attractive due to regulatory incentives and reduced competition. By expanding its pipeline, ERYTECH can diversify its revenue streams and reduce its reliance on eryaspase. The timeline for this expansion depends on the company's ability to secure funding and advance new product candidates through preclinical and clinical development. The market size for orphan drugs is projected to reach $262 billion by 2028.
- Partnerships and Collaborations: ERYTECH can pursue partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide access to funding, expertise, and distribution networks. The timeline for securing partnerships depends on the company's ability to demonstrate the value of its technology and product candidates. The global pharmaceutical market is estimated to be worth over $1.4 trillion.
- Geographic Expansion: ERYTECH can expand its operations into new geographic markets, such as Europe and Asia, to increase its market reach and revenue potential. The European market for cancer therapeutics is particularly attractive due to its large population and well-developed healthcare infrastructure. The timeline for geographic expansion depends on the company's ability to navigate regulatory requirements and establish a commercial presence in new markets. The European pharmaceutical market is the second largest in the world, valued at over $400 billion.
- Advancement of Erymethionase: ERYTECH's preclinical product candidate, erymethionase, represents a significant growth opportunity. By advancing erymethionase through preclinical and clinical development, ERYTECH can expand its pipeline and target methionine-dependent cancers. The timeline for this advancement depends on the company's ability to secure funding and demonstrate the safety and efficacy of erymethionase. The market for methionine-dependent cancer therapies is estimated to be worth billions of dollars.
- Orphan Drug Designation and Accelerated Approval Pathways: ERYTECH can leverage orphan drug designation and accelerated approval pathways to expedite the development and commercialization of its product candidates. Orphan drug designation provides regulatory incentives, such as market exclusivity and tax credits, while accelerated approval pathways allow for faster approval based on surrogate endpoints. The timeline for obtaining orphan drug designation and accelerated approval depends on the company's ability to meet the regulatory requirements. The orphan drug market is projected to grow significantly in the coming years.
Opportunities
- Expansion into new therapeutic areas.
- Partnerships with larger pharmaceutical companies.
- Geographic expansion.
- Advancement of erymethionase.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent infringement.
Competitive Advantages
- Proprietary red blood cell encapsulation technology.
- Patent protection for its product candidates.
- Clinical data supporting the efficacy and safety of its therapies.
- Orphan drug designation for certain indications.
About ERYP
ERYTECH Pharma S.A., established in 2004 and headquartered in Lyon, France, is a biopharmaceutical company dedicated to developing innovative therapies for cancer and orphan diseases. The company's core technology revolves around encapsulating therapeutic enzymes within red blood cells to enhance their efficacy and reduce systemic side effects. ERYTECH's lead product candidate, eryaspase, is a red blood cell-encapsulated L-asparaginase, designed to starve cancer cells of asparagine, an essential amino acid. Eryaspase is currently in Phase 3 clinical development for the treatment of second-line pancreatic cancer. Additionally, eryaspase is in Phase 2 clinical trials for triple-negative breast cancer and second-line acute lymphoblastic leukemia. Beyond eryaspase, ERYTECH is also developing erymethionase, a preclinical product candidate that utilizes red blood cells to deliver methionine-?-lyase, targeting methionine-dependent cancers. The company operates primarily in France and the United States, focusing on areas with significant unmet medical needs in oncology. With a team of 49 employees, ERYTECH is committed to advancing its pipeline and bringing novel therapies to patients with limited treatment options.
What They Do
- Develops red blood cell-based therapeutics for cancer.
- Focuses on treating pancreatic cancer, triple-negative breast cancer, and acute lymphoblastic leukemia.
- Utilizes a proprietary technology to encapsulate therapeutic enzymes within red blood cells.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approval for its product candidates from health authorities.
- Aims to commercialize its therapies to improve patient outcomes.
Business Model
- Develops and patents novel red blood cell-based therapeutics.
- Conducts clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approval for its products.
- Out-licenses or commercializes approved therapies.
Industry Context
ERYTECH Pharma S.A. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. ERYTECH's red blood cell-based therapeutic approach offers a unique delivery system that could differentiate it from competitors. However, the company faces competition from established pharmaceutical companies with greater resources and broader pipelines. The success of ERYTECH depends on its ability to navigate the regulatory landscape, secure funding, and demonstrate the clinical efficacy of its product candidates.
Key Customers
- Patients with cancer and orphan diseases.
- Oncologists and hematologists who prescribe the company's therapies.
- Hospitals and cancer centers that administer the company's therapies.
- Pharmaceutical companies that may partner with ERYTECH for development and commercialization.
Financials
Chart & Info
ERYTECH Pharma S.A. (ERYP) stock price: Price data unavailable
Latest News
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ERYP.
Price Targets
Wall Street price target analysis for ERYP.
MoonshotScore
What does this score mean?
The MoonshotScore rates ERYP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Gil Beyen
CEO
Gil Beyen is the Chief Executive Officer of ERYTECH Pharma S.A. He has extensive experience in the biopharmaceutical industry, with a focus on oncology and orphan diseases. Prior to joining ERYTECH, he held leadership positions at various pharmaceutical companies, where he was responsible for strategic planning, business development, and commercial operations. He has a strong track record of successfully launching and growing pharmaceutical products. His educational background includes advanced degrees in business and science.
Track Record: Under Gil Beyen's leadership, ERYTECH has advanced its lead product candidate, eryaspase, into Phase 3 clinical development for second-line pancreatic cancer. He has also overseen the expansion of the company's pipeline and the strengthening of its intellectual property portfolio. Beyen has focused on securing partnerships and collaborations to support the company's growth and development. He manages a team of 49 employees.
ERYTECH Pharma S.A. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. ERYP functions as a Level 2 ADR, meaning it is traded on a U.S. exchange (though not on the NYSE or NASDAQ) and registered with the SEC, offering increased visibility and potentially greater liquidity compared to Level 1 ADRs.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About ERYP
What does ERYTECH Pharma S.A. do?
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company specializing in the development of innovative red blood cell-based therapeutics for cancer and orphan diseases. Their core technology involves encapsulating therapeutic enzymes within red blood cells to enhance their efficacy and reduce systemic side effects. The company's lead product candidate, eryaspase, is currently in Phase 3 clinical development for second-line pancreatic cancer and Phase 2 for other indications. ERYTECH aims to improve patient outcomes by providing novel therapies for unmet medical needs in oncology.
What do analysts say about ERYP stock?
Analyst coverage of ERYP is limited, reflecting its small-cap status and clinical-stage nature. However, analysts generally focus on the potential of eryaspase in addressing unmet needs in pancreatic cancer and other indications. Key valuation metrics include the potential market size for eryaspase, the probability of clinical trial success, and the likelihood of regulatory approval. Growth considerations include the company's ability to secure funding, expand its pipeline, and commercialize its products. Analyst consensus is pending further data from ongoing clinical trials. There is no consensus to buy or sell.
What are the main risks for ERYP?
The main risks for ERYP include the potential failure of clinical trials, particularly the Phase 3 trial for eryaspase in pancreatic cancer. Regulatory hurdles and delays in obtaining approval from health authorities also pose significant risks. Competition from established pharmaceutical companies with greater resources and broader pipelines could limit ERYP's market share. The company's dependence on the success of eryaspase, with limited diversification of its product pipeline, further increases its vulnerability. Securing sufficient funding to support ongoing research and development activities is also a critical risk.
What are the key factors to evaluate for ERYP?
ERYTECH Pharma S.A. (ERYP) currently holds an AI score of 51/100, indicating moderate score. Key strength: Proprietary red blood cell encapsulation technology.. Primary risk to monitor: Potential: Failure of the Phase 3 clinical trial of eryaspase in second-line pancreatic cancer.. This is not financial advice.
How frequently does ERYP data refresh on this page?
ERYP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ERYP's recent stock price performance?
Recent price movement in ERYTECH Pharma S.A. (ERYP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary red blood cell encapsulation technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ERYP overvalued or undervalued right now?
Determining whether ERYTECH Pharma S.A. (ERYP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ERYP?
Before investing in ERYTECH Pharma S.A. (ERYP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.